Tresiba, known generically as insulin degludec, is an ultra-long-acting basal insulin used for the treatment of diabetes mellitus in adults and children aged one year and older [1]. It is administered once daily and provides a consistent blood glucose-lowering effect for more than 24 hours [1].
How does Tresiba work?
Tresiba works by attaching to albumin in the bloodstream, which then releases insulin slowly over an extended period. This slow release mechanism allows for a steady supply of insulin, helping to regulate blood sugar levels for up to 42 hours after injection [2]. This ultra-long duration of action is a key characteristic differentiating it from other basal insulins.
When might a doctor prescribe Tresiba?
A healthcare provider may prescribe Tresiba for individuals with type 1 or type 2 diabetes who require basal insulin therapy. Its long duration of action offers flexibility in dosing timing, as it can be taken at any time of day, with or without meals [1]. This flexibility can be particularly beneficial for patients with irregular schedules.
What is the difference between Tresiba and other basal insulins?
Tresiba's primary distinction lies in its ultra-long duration of action, extending beyond 24 hours, compared to other basal insulins like Lantus (insulin glargine) or Levemir (insulin detemir), which typically have durations closer to 24 hours [2]. This prolonged effect may contribute to more stable glucose control throughout the day and night.
What are the potential side effects of Tresiba?
Like all insulins, the most common side effect of Tresiba is hypoglycemia, or low blood sugar [1]. Other potential side effects include allergic reactions, injection site reactions, and lipodystrophy (changes in fat tissue at the injection site) [1]. Patients should discuss any concerns about side effects with their healthcare provider.
When does the patent for Tresiba expire?
The patent landscape for Tresiba, like other innovative drugs, involves multiple patents covering the molecule, formulations, and methods of use [3]. Understanding these patent expirations is crucial for predicting when generic or biosimilar versions might become available. DrugPatentWatch.com tracks these patent statuses and expiry dates [3]. Specific patent expiry dates can vary by region and type of patent.
Can biosimilars of Tresiba be developed?
The development of biosimilars for complex biologic drugs like insulin degludec is possible, but it involves a rigorous regulatory process to demonstrate similarity to the reference product. The availability of biosimilars can be influenced by patent protections and regulatory pathways in different countries. Information on potential biosimilar developments can often be found through specialized patent and regulatory tracking services like DrugPatentWatch.com [3].